BRIEF-Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes

Biomea Fusion Inc

Biomea Fusion Inc

BMEA

0.00

June 5 (Reuters) - Biomea Fusion Inc BMEA.O:

  • BIOMEA FUSION PRESENTS NEW CLINICAL AND TRANSLATIONAL DATA FOR ICOVAMENIB AT THE AMERICAN DIABETES ASSOCIATION (“ADA”) 86TH SCIENTIFIC SESSIONS AND ANNOUNCES EXPANSION OF ONGOING PHASE I BMF-650 STUDY

  • BIOMEA FUSION - ICOVAMENIB DATA SHOW MUSCLE PRESERVATION AND FAT REDUCTION IN OBESITY AND DIABETES

  • BIOMEA FUSION - ICOVAMENIB IMPROVES HBA1C AND C-PEPTIDE IN TYPE 1 DIABETES WITH NO IMMUNE ACTIVATION

  • BIOMEA FUSION: EXPANDED PHASE I BMF-650 STUDY TO EVALUATE A RAPID ONE-STEP TITRATION, ENHANCED WEIGHT LOSS POTENTIAL WITH ORAL GLP-1 RECEPTOR AGONIST

Source text: ID:nGNX63lwrN

Further company coverage: BMEA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.